Anavex Life Sciences (AVXL) Hits New 52-Week Low at $3.00
Anavex Life Sciences Corp. (NASDAQ:AVXL)’s share price reached a new 52-week low on Tuesday . The company traded as low as $3.00 and last traded at $3.01, with a volume of 891109 shares. The stock had previously closed at $3.40.
A number of equities analysts have recently weighed in on the company. Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences in a report on Tuesday, December 12th. Maxim Group set a $14.00 price target on Anavex Life Sciences and gave the stock a “buy” rating in a report on Monday, December 11th. ValuEngine cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, November 21st. Finally, Zacks Investment Research raised Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Tuesday, September 26th.
The stock has a market capitalization of $133.10, a price-to-earnings ratio of -9.33 and a beta of 0.94.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Anavex Life Sciences by 8.9% in the second quarter. Vanguard Group Inc. now owns 1,617,757 shares of the biotechnology company’s stock valued at $8,606,000 after purchasing an additional 132,076 shares during the period. State Street Corp grew its position in shares of Anavex Life Sciences by 15.2% in the second quarter. State Street Corp now owns 603,326 shares of the biotechnology company’s stock valued at $3,210,000 after purchasing an additional 79,516 shares during the period. SNS Financial Group LLC purchased a new stake in shares of Anavex Life Sciences in the third quarter valued at $290,000. Northern Trust Corp grew its position in shares of Anavex Life Sciences by 16.0% in the second quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock valued at $2,282,000 after purchasing an additional 59,069 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new stake in shares of Anavex Life Sciences in the second quarter valued at $186,000. 22.70% of the stock is owned by institutional investors.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.